FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2743001405> ?p ?o ?g. }

• W2743001405 endingPage "99" @default.
• W2743001405 startingPage "91" @default.
• W2743001405 abstract "New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer Maiko Niki, Takashi Yokoi, Takayasu Kurata, Shosaku Nomura First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka, Japan Background: Several biomarkers have emerged as potential prognostic and predictive markers for non-small-cell lung cancer (NSCLC). Successful inhibition of angiogenesis with the anti-vascular endothelial growth factor antibody, bevacizumab, has improved the efficacy seen with standard cytotoxic therapy of NSCLC. However, despite such enhanced treatment strategies, the prognosis for patients with advanced NSCLC remains poor. Patients and methods: We assessed potential biomarkers in 161 NSCLC patients and 42 control patients. Enzyme-linked immunosorbent assay methods were used to evaluate three biomarkers: platelet-derived microparticle (PDMP), high-mobility group box-1 (HMGB1), and plasminogen activator inhibitor-1 (PAI-1). We studied the effects of bevacizumab on the expression of these markers. We also analyzed the relationship of the newly designed risk factor (NDRF) to overall survival and disease-free survival. The NDRF classification of patients was determined from the levels of PDMP, HMGB1, and PAI-1. To determine the individual prognostic power of PDMP, HMGB1, and PAI-1, we evaluated associations between their levels and patient outcomes by Kaplan–Meier survival analysis in a derivation cohort. Results: PDMP, HMGB1, and PAI-1 levels were higher in NSCLC patients compared with control patients. Notably, the difference in PDMP levels exhibited the strongest statistical significance (p<0.001). Multivariate analysis showed that HMGB1 and PAI-1 levels were significantly correlated with PDMP levels. Patients who received standard chemotherapy with bevacizumab exhibited significantly reduced levels of all three markers compared with patients who received standard chemotherapy. NDRF3 status (high levels of all three markers) was significantly correlated with a poor prognosis (p<0.05 for overall survival and disease-free survival). Conclusion: Our results demonstrate that abnormal levels of PDMP, HMGB1, and PAI-1 are related to each other in NSCLC. Moreover, our findings suggest that the vascular complications associated with these markers may contribute to a poor prognosis for NSCLC patients. Keywords: non-small-cell lung cancer, platelet-derived microparticle, HMGB1, PAI-1, bevacizumab&nbsp" @default.
• W2743001405 created "2017-08-17" @default.
• W2743001405 creator A5005318923 @default.
• W2743001405 creator A5006336889 @default.
• W2743001405 creator A5063817865 @default.
• W2743001405 creator A5067399580 @default.
• W2743001405 date "2017-08-01" @default.
• W2743001405 modified "2023-10-06" @default.
• W2743001405 title "New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer" @default.
• W2743001405 cites W1029258801 @default.
• W2743001405 cites W1505798668 @default.
• W2743001405 cites W1915526309 @default.
• W2743001405 cites W1954967105 @default.
• W2743001405 cites W1967434989 @default.
• W2743001405 cites W1967947451 @default.
• W2743001405 cites W1969328947 @default.
• W2743001405 cites W1974165456 @default.
• W2743001405 cites W1975741271 @default.
• W2743001405 cites W1979538859 @default.
• W2743001405 cites W1984413085 @default.
• W2743001405 cites W1989515923 @default.
• W2743001405 cites W1989664813 @default.
• W2743001405 cites W1992476844 @default.
• W2743001405 cites W1993312546 @default.
• W2743001405 cites W1993980146 @default.
• W2743001405 cites W2005244154 @default.
• W2743001405 cites W2016261481 @default.
• W2743001405 cites W2027456034 @default.
• W2743001405 cites W2032784036 @default.
• W2743001405 cites W2033377234 @default.
• W2743001405 cites W2034585518 @default.
• W2743001405 cites W2036573487 @default.
• W2743001405 cites W2037754934 @default.
• W2743001405 cites W2041251523 @default.
• W2743001405 cites W2044201404 @default.
• W2743001405 cites W2045220907 @default.
• W2743001405 cites W2048128186 @default.
• W2743001405 cites W2050624503 @default.
• W2743001405 cites W2065449932 @default.
• W2743001405 cites W2072671591 @default.
• W2743001405 cites W2075035271 @default.
• W2743001405 cites W2084740377 @default.
• W2743001405 cites W2088372160 @default.
• W2743001405 cites W2090621693 @default.
• W2743001405 cites W2096134439 @default.
• W2743001405 cites W2103662104 @default.
• W2743001405 cites W2104347254 @default.
• W2743001405 cites W2109134893 @default.
• W2743001405 cites W2115720818 @default.
• W2743001405 cites W2118397697 @default.
• W2743001405 cites W2120356858 @default.
• W2743001405 cites W2120420501 @default.
• W2743001405 cites W2121948151 @default.
• W2743001405 cites W2125723884 @default.
• W2743001405 cites W2132075674 @default.
• W2743001405 cites W2132762930 @default.
• W2743001405 cites W2141544811 @default.
• W2743001405 cites W2144660856 @default.
• W2743001405 cites W2145835533 @default.
• W2743001405 cites W2145950952 @default.
• W2743001405 cites W2153628956 @default.
• W2743001405 cites W2158743409 @default.
• W2743001405 cites W2160414927 @default.
• W2743001405 cites W2166715517 @default.
• W2743001405 cites W2168197710 @default.
• W2743001405 cites W2168959119 @default.
• W2743001405 cites W2170552969 @default.
• W2743001405 cites W2171851177 @default.
• W2743001405 cites W2213433074 @default.
• W2743001405 cites W2339922740 @default.
• W2743001405 cites W2418443178 @default.
• W2743001405 cites W2490543344 @default.
• W2743001405 cites W2560809537 @default.
• W2743001405 cites W2566863750 @default.
• W2743001405 cites W2572174216 @default.
• W2743001405 cites W3108750466 @default.
• W2743001405 doi "https://doi.org/10.2147/lctt.s138887" @default.
• W2743001405 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5546813" @default.
• W2743001405 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28814907" @default.
• W2743001405 hasPublicationYear "2017" @default.
• W2743001405 type Work @default.
• W2743001405 sameAs 2743001405 @default.
• W2743001405 citedByCount "12" @default.
• W2743001405 countsByYear W27430014052018 @default.
• W2743001405 countsByYear W27430014052019 @default.
• W2743001405 countsByYear W27430014052020 @default.
• W2743001405 countsByYear W27430014052021 @default.
• W2743001405 countsByYear W27430014052022 @default.
• W2743001405 crossrefType "journal-article" @default.
• W2743001405 hasAuthorship W2743001405A5005318923 @default.
• W2743001405 hasAuthorship W2743001405A5006336889 @default.
• W2743001405 hasAuthorship W2743001405A5063817865 @default.
• W2743001405 hasAuthorship W2743001405A5067399580 @default.
• W2743001405 hasBestOaLocation W27430014051 @default.
• W2743001405 hasConcept C126322002 @default.
• W2743001405 hasConcept C143998085 @default.
• W2743001405 hasConcept C2776256026 @default.
• W2743001405 hasConcept C2776694085 @default.

• next